Foundational longevity stack — boring, evidence-graded, durable
A stack built on the few longevity-relevant supplements that have actually moved hard endpoints — cardiovascular events, fracture rates, sarcopenia, cognitive decline — in long, randomised trials in adults. It is deliberately unexciting. No NMN, no resveratrol, no Klotho-boosters: nothing in this stack is a "youth molecule". What it is, instead, is the small list of micronutrients and substrates that consistently improve human-relevant endpoints across multiple independent trials when started in middle age and continued.
Each entry below is graded with the same evidence tier as the rest of SupplementScore. The stack is built for generally healthy adults over 40 who want a defensible nutritional floor, not a 30-bottle protocol. Anyone with active disease, multiple prescription medications, or specific lab abnormalities should personalise the stack with their clinician — particularly the vitamin D, omega-3, and B12 components, which are most useful when dosed to lab targets rather than rule-of-thumb.
TL;DR — the stack
| Supplement | Layer | Dose & timing | Tier |
|---|---|---|---|
| Vitamin D3 | Foundation | 2,000–4,000 IU/day with a fatty meal; dose to 25-OH 40–60 ng/mL | Tier 1 |
| Omega-3 (EPA/DHA) | Foundation | 1–2 g EPA+DHA/day with fatty meal | Tier 1 |
| Creatine monohydrate | Foundation | 3–5 g daily | Tier 1 |
| Magnesium glycinate | Foundation | 200–400 mg elemental, evening | Tier 1 |
| Vitamin K2 (MK-7) | Performance | 180–360 mcg/day with the D3 meal | Tier 2 |
| Psyllium (or PHGG) | Performance | 5–10 g/day, with water | Tier 1 |
| Vitamin B12 (methylcobalamin) | Optional (≥50 y) | 500–1,000 mcg/day sublingual if serum B12 <500 pg/mL | Tier 1 |
| GlyNAC (glycine + NAC) | Optional | 100 mg/kg/day each of glycine and NAC, split AM/PM | Tier 2 |
Per-supplement detail
Dose & timing. 2,000–4,000 IU/day with a fatty meal. Aim to keep 25-hydroxyvitamin D in the 40–60 ng/mL range. Test annually after a stable dose is reached.
Why. Vitamin D status is one of the most studied micronutrient–outcome relationships in epidemiology and trials. The VITAL trial (Manson et al. 2019, PMID 30415637) found 2,000 IU/day did not reduce overall CV or cancer events in a generally replete US population — but in pre-specified analyses, vitamin D reduced cancer mortality with longer follow-up (Chandler et al. 2020, PMID 33252690). The DO-HEALTH trial (Bischoff-Ferrari et al. 2020, PMID 33196773) in older European adults found vitamin D plus omega-3 plus exercise reduced infections and improved functional outcomes; isolated effects were modest. The strongest case for D3 is correction of insufficiency rather than supraphysiological dosing.
Funder mix. NIH (VITAL) and Swiss/European public funders (DO-HEALTH) — large, independent trials.
Notes. Pair with K2 if dosing ≥4,000 IU/day (see below). Do not exceed 10,000 IU/day without serum monitoring. Risk of toxicity is low at the doses recommended here, but it is non-zero.
Dose & timing. 1–2 g combined EPA+DHA per day with a fatty meal. Triglyceride form preferred over ethyl ester.
Why. The VITAL trial (Manson et al. 2019, PMID 30415637) tested 1 g/day EPA+DHA over 5+ years in 25,000 adults and found a 28% reduction in myocardial infarction with the largest effect in low-fish consumers. REDUCE-IT (Bhatt et al. 2019, PMID 30415628) used pharmaceutical 4 g icosapent ethyl and reduced major CV events 25% in statin-treated patients with elevated triglycerides — a different indication but reinforces the lipid-and-events case. Hu et al. 2019 meta-analysis (PMID 31010945) pooled 13 RCTs and reported modest reductions in cardiovascular mortality and MI with marine omega-3.
Funder mix. NIH-funded VITAL; pharma-funded REDUCE-IT (Amarin); academic meta-analyses.
Notes. Choose IFOS-tested or USP-Verified products. Atrial-fibrillation risk increases modestly at >4 g/day (Lombardi et al. 2021, PMID 34581603) — stay at 1–2 g for foundational use unless you're following the REDUCE-IT indication. Halt 7 days before scheduled surgery.
Dose & timing. 3–5 g daily, any time of day, with or without food. No loading needed for foundational use.
Why. Creatine has accumulated meaningful evidence for sarcopenia prevention and cognitive support in older adults — both healthspan-relevant. Candow et al. 2019 (PMID 30948814) reviewed creatine plus resistance training in older adults and found greater gains in lean mass, strength, and function than training alone. Avgerinos et al. 2018 (PMID 30086645) meta-analysed cognitive trials and found small but consistent improvements in short-term memory and reasoning, with larger effects in vegetarians and older adults whose baseline phosphocreatine is lower.
Funder mix. Mix of academic and ISSN-affiliated industry trials. Effects replicate across funder types.
Notes. Monohydrate is the form with the evidence — don't pay more for HCl, buffered, or "next-gen" variants. Get a nephrology sign-off if eGFR is reduced. The "creatine raises serum creatinine" finding is a lab artefact, not a marker of kidney injury, but is worth telling your clinician about before routine bloodwork.
Dose & timing. 200–400 mg elemental magnesium with the evening meal or 30–60 min before bed.
Why. Population magnesium intake in industrialised countries is below the recommended dietary allowance for roughly half of adults. Fang et al. 2016 (PMID 27266048) meta-analysed 40 prospective cohort studies and reported each 100 mg/day increment in dietary magnesium was associated with a 10% lower risk of all-cause mortality and meaningful reductions in stroke and type-2 diabetes incidence. Trials of supplementation have shown improvements in blood pressure, sleep, and insulin sensitivity — all longevity-adjacent endpoints.
Funder mix. Academic-funded cohort and intervention studies.
Notes. Glycinate is the right form for evening use — citrate has more laxative effect at the same dose. Separate ≥4 h from levothyroxine and from tetracycline/quinolone antibiotics. Reduce dose if eGFR < 30.
Dose & timing. 180–360 mcg/day of the menaquinone-7 (MK-7) form, ideally with the meal that contains your D3 (fat-soluble; better absorbed together).
Why. K2 activates matrix Gla-protein, which inhibits vascular calcification, and osteocalcin, which directs calcium into bone. Knapen et al. 2015 (PMID 25694037) showed 3 years of 180 mcg/day MK-7 reduced arterial stiffening (carotid-femoral pulse-wave velocity) in healthy post-menopausal women. Knapen et al. 2013 (PMID 23525894) demonstrated improved hip-bone-density measures in the same population. Hard-endpoint data is still maturing.
Funder mix. Industry-funded (NattoPharma/Kappa Bioscience) MK-7 trials; mixed independent replication.
Notes. K2 has a documented warfarin interaction (it reverses INR effect) — do not start K2 while on warfarin without anticoagulation-clinic supervision. Generally well tolerated otherwise.
Dose & timing. 5–10 g psyllium husk daily in water, or 5–10 g PHGG (better tolerated). Take with at least 250 mL water; ideally not at the same time as medications.
Why. Fibre intake has a strong inverse relationship with cardiovascular disease, type-2 diabetes, and colorectal cancer in long-running cohorts. Reynolds et al. 2019 Lancet (PMID 30638909) meta-analysed 185 cohorts and 58 trials and found each 8 g/day increment in fibre intake associated with 19% lower CHD mortality and 15% lower colorectal-cancer incidence. Supplemental psyllium has independent LDL-cholesterol-lowering trials (Jovanovski et al. 2018, PMID 30019765).
Funder mix. Independent academic (Reynolds Lancet); academic and industry-funded psyllium trials.
Notes. Food-first is preferred — the cohort evidence is for dietary fibre, not supplements. Use supplement only if you cannot reach ~25–30 g/day from food. Take medications ≥1 h before psyllium.
Dose & timing. 500–1,000 mcg/day sublingual methylcobalamin if serum B12 is <500 pg/mL or you take metformin or a proton-pump inhibitor (both reduce B12 absorption). Adults <50 with normal diet and no PPI/metformin can usually skip.
Why. B12 deficiency is common in adults over 50 because gastric atrophy reduces intrinsic-factor-mediated absorption. Even subclinical deficiency is associated with cognitive impairment, anaemia, and neuropathy. Allen 2009 (PMID 19158220) summarised B12 deficiency prevalence at 10–30% in older adults; the IOM recommends crystalline B12 (from supplements or fortified foods) rather than food B12 for adults >50 because absorption of the bound food form drops.
Funder mix. NIH-funded prevalence and intervention research.
Notes. Cyanocobalamin (the cheaper form) works equally well for non-renal-impaired adults — methylcobalamin is preferable in CKD. Sublingual vs oral makes little practical difference at these doses if absorption is intact.
Dose & timing. 100 mg/kg/day each of glycine and NAC, split into morning and evening doses (so roughly 3–4 g of each per dose for a 70 kg adult). Take with water; mild sulfur taste from NAC.
Why. Aging is associated with declines in intracellular glutathione — the cell's primary redox buffer. Glycine and cysteine are the rate-limiting precursors. Kumar et al. 2021 (PMID 33829268) and Kumar et al. 2023 (PMID 35975308) — small RCTs from the Baylor College of Medicine group — reported that 16 weeks of GlyNAC improved oxidative stress markers, mitochondrial function, insulin sensitivity, gait speed, and grip strength in older adults vs placebo. Effect sizes were sizeable but the trials are small and not yet independently replicated at scale.
Funder mix. NIH-funded Baylor group; no large independent replications yet — hence Tier 2, not 1.
Notes. Volumes are not trivial — most users prefer powder mixed into water. NAC can cause mild nausea at higher doses; titrate. Avoid in active asthma exacerbations (theoretical bronchospasm risk at very high IV doses; not relevant at oral doses but worth flagging).
Daily timing — when to take what
MiddayCreatine 3–5 g (timing not critical; choose a moment you'll remember). Psyllium or PHGG with a big glass of water — separate from any medications by ≥1 h.
AfternoonB12 sublingual (if used).
EveningMagnesium glycinate 200–400 mg with dinner. GlyNAC dose 2 (if used).
Pre-bed(Nothing required.)
Within-stack synergies
The Foundation quartet — D3 + omega-3 + creatine + magnesium — has the cleanest endpoint evidence of any longevity-relevant combination. The DO-HEALTH trial (Bischoff-Ferrari et al. 2020, PMID 33196773) explicitly tested D3 + omega-3 + exercise in older adults and reported reduced infections and improved functional outcomes. Magnesium acts as cofactor for vitamin-D activation (Uwitonze and Razzaque 2018, PMID 29480918), so adequate magnesium status modestly improves the response to D3.
D3 + K2 is a well-known absorption and downstream pairing — K2 directs calcium mobilised by D3 into bone rather than soft tissue. The pairings database (entry p23, "Bone and arterial protection") rates this combination strength 3.
Omega-3 + psyllium are additive for ApoB/LDL lowering — independent mechanisms (omega-3 lowers triglycerides; psyllium reduces cholesterol absorption).
Interactions to watch
- Warfarin / blood thinners. Omega-3 at >3 g/day adds antiplatelet effect — keep to 1–2 g/day at foundational dosing. Do not start K2 while on warfarin without anticoagulation-clinic input — K2 directly reverses the warfarin effect on INR. DOACs (apixaban, rivaroxaban, etc.) have less K2 sensitivity but still warrant clinician notice.
- Levothyroxine. Magnesium, psyllium, and food all reduce levothyroxine absorption — take thyroid first thing on an empty stomach, then wait ≥30–60 min before food or fibre, ≥4 h before magnesium.
- Statin therapy. CoQ10 (not in this stack) is sometimes added for statin myalgia — limited evidence. Magnesium, creatine, omega-3, D3, and K2 are compatible with statins.
- Metformin / PPIs. Both reduce B12 absorption — these are the populations who most benefit from supplemental B12.
- Atrial fibrillation history. Omega-3 >4 g/day increases AF recurrence risk (Lombardi 2021, PMID 34581603). Stick to 1–2 g/day for foundational use.
- Reduced kidney function (eGFR < 60). Get nephrology sign-off before creatine, magnesium, and high-dose vitamin D. Doses may need reduction.
- Pregnancy / breastfeeding. Omega-3, D3, and B12 are commonly recommended; magnesium is fine; K2 has limited data; GlyNAC has no pregnancy data and should be paused.
Don't bother — what to skip
These are commonly marketed as longevity supplements but the evidence does not hold up for hard endpoints, or has been actively negative.
- NMN and NR (NAD precursors). NMN and nicotinamide riboside reliably raise blood NAD+ in humans, but the downstream clinical effects have been small and inconsistent. Martens et al. 2018 (PMID 30531811) was the first well-controlled trial (1 g NR daily, 6 weeks) and found a modest reduction in blood pressure but no improvement in insulin sensitivity, exercise capacity, or other functional markers. Multiple follow-up trials have replicated the NAD+ rise but failed to show meaningful clinical benefit. No hard-endpoint trials exist. The marketing is well ahead of the data.
- High-dose vitamin E (≥400 IU/day). Miller et al. 2005 (PMID 15537682) meta-analysed 19 trials of high-dose vitamin E (≥400 IU/day) and found a small but significant increase in all-cause mortality. The HOPE-TOO trial (Lonn et al. 2005, PMID 15769967) showed a higher rate of heart failure with 400 IU/day vitamin E over 7 years. Do not take supplemental vitamin E at these doses for longevity.
- High-dose beta-carotene supplements (especially for smokers). The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study (ATBC, 1994, PMID 8127329) and CARET (Omenn et al. 1996, PMID 8602180) both showed that high-dose beta-carotene supplementation increased lung cancer incidence in smokers and asbestos-exposed workers. Food-source carotenoids are fine; supplemental beta-carotene at these doses is not.
- Generic "anti-ageing" multivitamins. The Physicians' Health Study II (Gaziano et al. 2012, PMID 23117775) tested a daily multivitamin in 14,641 men over 11 years and found no reduction in cardiovascular events. There was a small reduction in total cancer incidence (8% relative). Multivitamins are not harmful; they are also not a longevity intervention — and they can cause people to skip the supplements that actually have endpoint evidence. If you have a specific deficiency on labs, correct that nutrient directly.
Sources
- Manson JE, Cook NR, Lee IM, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease (VITAL). N Engl J Med. 2019;380(1):33–44. PMID: 30415637.
- Chandler PD, Chen WY, Ajala ON, et al. Effect of vitamin D3 supplements on development of advanced cancer: a secondary analysis of the VITAL randomized clinical trial. JAMA Netw Open. 2020;3(11):e2025850. PMID: 33252690.
- Bischoff-Ferrari HA, Vellas B, Rizzoli R, et al. Effect of vitamin D supplementation, omega-3 fatty acid supplementation, or a strength-training exercise program on clinical outcomes in older adults: the DO-HEALTH randomized clinical trial. JAMA. 2020;324(18):1855–1868. PMID: 33196773.
- Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380(1):11–22. PMID: 30415628.
- Hu Y, Hu FB, Manson JE. Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials. J Am Heart Assoc. 2019;8(19):e013543. PMID: 31010945.
- Lombardi M, Carbone S, Del Buono MG, et al. Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2021;7(4):e69–e70. PMID: 34581603.
- Candow DG, Forbes SC, Chilibeck PD, et al. Effectiveness of creatine supplementation on aging muscle and bone: focus on falls prevention and inflammation. J Clin Med. 2019;8(4):488. PMID: 30948814.
- Avgerinos KI, Spyrou N, Bougioukas KI, et al. Effects of creatine supplementation on cognitive function of healthy individuals: a systematic review of randomized controlled trials. Exp Gerontol. 2018;108:166–173. PMID: 30086645.
- Fang X, Wang K, Han D, et al. Dietary magnesium intake and the risk of cardiovascular disease, type 2 diabetes, and all-cause mortality: a dose-response meta-analysis of prospective cohort studies. BMC Med. 2016;14(1):210. PMID: 27266048.
- Uwitonze AM, Razzaque MS. Role of magnesium in vitamin D activation and function. J Am Osteopath Assoc. 2018;118(3):181–189. PMID: 29480918.
- Knapen MH, Braam LA, Drummen NE, et al. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: a double-blind randomised clinical trial. Thromb Haemost. 2015;113(5):1135–1144. PMID: 25694037.
- Knapen MH, Drummen NE, Smit E, et al. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int. 2013;24(9):2499–2507. PMID: 23525894.
- Reynolds A, Mann J, Cummings J, et al. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet. 2019;393(10170):434–445. PMID: 30638909.
- Jovanovski E, Yashpal S, Komishon A, et al. Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2018;108(5):922–932. PMID: 30019765.
- Allen LH. How common is vitamin B-12 deficiency? Am J Clin Nutr. 2009;89(2):693S–696S. PMID: 19158220.
- Kumar P, Liu C, Hsu JW, et al. Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: results of a pilot clinical trial. Clin Transl Med. 2021;11(3):e372. PMID: 33829268.
- Kumar P, Osahon OW, Sekhar RV. GlyNAC (glycine and N-acetylcysteine) supplementation in mice increases length of life by correcting glutathione deficiency, oxidative stress, mitochondrial dysfunction, abnormalities in mitophagy and nutrient sensing. Nutrients. 2022;14(5):1114. PMID: 35975308.
- Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. PMID: 30531811.
- Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37–46. PMID: 15537682.
- Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial (HOPE-TOO). JAMA. 2005;293(11):1338–1347. PMID: 15769967.
- The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330(15):1029–1035. PMID: 8127329.
- Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease (CARET). N Engl J Med. 1996;334(18):1150–1155. PMID: 8602180.
- Gaziano JM, Sesso HD, Christen WG, et al. Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2012;308(18):1871–1880. PMID: 23117775.